CDT6-expression can alter tumor sensitivity to chemotherapy

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 443-446

  Bouïs, Diane ^a   Hospers, Geke A P ^a   Meijer, Coby ^a   Dam, Wendy ^a   Mulder, Nanno H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

AngX; Anti angiogenic; CDT6; Chemotherapy; Gene therapy; Sensitivity

Indexed keywords

ANGIOPOIETIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CELL LINE; CONTROLLED STUDY; CORNEA DERIVED TRANSCRIPT 6 GENE; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CLONING, MOLECULAR; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; GENE THERAPY; MELANOMA, EXPERIMENTAL; MICE; PACLITAXEL; TRANSFECTION; VINCRISTINE;

EID: 0037231198     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Peek R, Kammerer RA, Frank S, Otte I and Westphal JR: The angiopoietin-like factor CDT6 is a putative morphogen for human cornea. J Biol Chem 277(1): 686-93, 2001.
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L and Cavazzana-Calvo M: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346(16): 1185-93, 2002.
3. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K and Isner JM: Constitutive expression of PhVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97(12): 1114-23, 1998.
4. Tanaka M and Grossman HB: Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis and synergy with cisplatin. Hum Gene Ther 12(18): 2225-36, 2001.
5. Peek R, van Gelderen E, Bruinenberg M and Kijlstra A: Molecular cloning of a new angiopoietin-like factor from the human cornea. invest ophtalmol Vis Sci 39(10): 1782-8, 1998.
6. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TJ, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, Huang T, Ppapdopoulos N, Maisonpierre PC, Davis S and Yancopoulos GD: Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96: 1904-9, 1999.
7. Peek R, Kammerer RA, Frank S, Otte I and Westphal JR: The angiopoietin-like factor CDT6 is a putative morphogen for human cornea. J Biol Chem 277(1): 686-93, 2001.
8. Fidler IJ and Nicholson GL: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor cell lines. J Natl Cancer Inst 57(5): 1199-202, 1976.
9. Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH and de Vries EG: Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 71(4): 684-90, 1995.
10. Nielsen D, Maare C and Skovsgaard T: Cellular resistance to anthracyclines. Gen Pharmacol 27(2): 251-5, 1996.
11. Shiraga K, Sakaguchi K, Senoh T, Ohta T, Ogawa S, Sawayama T, Mouri H, Fujiwara A and Tsuji T: Modulation of doxorubicin sensitivity by cyclosporine a in hepatocellular carcinoma cells and their doxorubicin-resistant sublines. J Gastroenterol Hepatol 16(4): 460-6, 2001.
12. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Mollgard L, Lehman S, Xu D, Covelli A, Gustavsson B and Paul C: P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 18(9): 1837-44, 2000.
13. Liu QY and Tan BK: Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sci 67(10): 1207-18, 2000.
14. Timmer-Bosscha H, Hospers GA, Meijer C, Mulder NH, Muskiet FA, Martini IA, Uges DR and de Vries EG: Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell Line. J Natl Cancer Inst 81(14): 1069-75, 1989.
15. Boisdron-Celle M, Craipeau C, Brienza S, Delva R, Guerin-Meyer V, Cvitkovic E and Gamelin E: Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol 49(3): 235-43, 2002.
16. Cassidy J: Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract 54(6): 399-402, 2000.
17. Scheithauer W, Rosen H, Schiessel R, Schuller J, Karall M, Ernst F, Sebesta C, Kornek G, Hentschel E and Marczell A: Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin. Cancer 67(5): 1294-8, 1991.
18. Tsai CM, Hsiao SH, Frey CM, Chang KT, Perng RP, Gazdar AF and Kramer BS: Combination cytotoxic effects of cisdiamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. Cancer Res 53(5): 1079-84, 1993.
19. Vivat-Hannah V, You D, Rizzo C, Daris JP, Lapointe P, Zusi FC, Marinier A, Lorenzi MV and Gottardis MM: Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). Cancer Res 61(24): 8703-11, 2001.
20. Caffo O: Radiosensitization with chemotherapeutic agents. Lung Cancer 34 Suppl 4: S81-S90, 2001.
21. Gritti LMF, Beviacqua M, Bordenave RH and Rumi LS: Interferon-alpha 2b modulation of doxorubicin sensitivity in a multidrug resistant cell line. J Exp Clin Cancer Res 20(3): 393-400, 2001.
22. Borsellino N, Crescimanno M, Flandina C, Flugy A and D'Alessandro N: Combined activity of interleukin-1 alpha of TNF-alpha and doxorubicin on multidrug resistant cell lines: Evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects. Anticancer Res 14(6B): 2643-8, 1994.
23. Barancik M, Docolomansky P, Slezak J and Breier A: Overcoming of vincristine resistance in L1210/VCR cells by several corticosteroids. collateral sensitivity of resistant cells. Neoplasma 40(1): 21-5, 1993.
24. Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M, Hirata S and Watanabe H: Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res 58(23): 5565-9, 1998.
25. Dias S, Choy M, Alitalo K and Rafii S: Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival and resistance to chemotherapy. Blood 99(6): 2179-84, 2002.
26. Dias S, Shmelkov SV, Lam G and Rafii S: VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99(7): 2532-40, 2002.
27. Peek R, van Gelderen E, Bruinenberg M and Kijlstra A: Molecular cloning of a new angiopoietinlike factor from the human cornea. Invest Ophtalmol Vis Sci 39(10): 1782-8, 1998.
28. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TJ, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, Huang T, Ppapdopoulos N, Maisonpierre PC, Davis S and Yancopoulos GD: Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96: 1904-9, 1999.
29. Liu Y, Paradis H, Gendron RL, Choi DW, Chapon P, Tseng SCG, Kao CWC and Kao WWY: AngX/CDT6 a novel fibrinogen/angiopoietin-like factor that enhances angiogenesis in vivo. Invest Ophtalmol Vis Sci 42(4): S478, 2001.
30. Supino R, Mariani M, Colombo A, Prosperi E, Croce AC and Bottiroli G: Comparative studies on the effects of doxorubicin and differentiation inducing agents on B16 melanoma cells. Eur J Cancer 28A(4-5): 778-83, 1992.